PPARG2 Pro12Ala polymorphism influences body composition changes in severely obese patients consuming extra virgin olive oil: a randomized clinical trial.

ABSTRACT: Background:Previous intervention studies have reported the association of the PPARG2 Pro12Ala (rs1801282) and IL6 -174G?>?C (rs1800795) polymorphisms with weight loss; however, their results are inconsistent. We aimed to investigate the effect of the PPARG2 Pro12Ala and IL6 -174G?>?C polymorphisms on body weight, body composition and metabolic parameters after a 12-week nutritional intervention with a traditional Brazilian diet and extra virgin olive oil supplementation in severely obese patients. Methods:A total of 149 severely obese individuals [body mass index (BMI)???35 kg/m2] were randomized into three 12-week nutritional intervention groups - the extra virgin olive oil supplementation (OO) group (n?=?50), the traditional Brazilian diet (DieTBra) group (n?=?49), and the DieTBra plus extra virgin olive oil supplementation (DieTBra+OO) group (n?=?50). Anthropometric measurements, body composition, metabolic parameters, physical activity practise and dietary intake were assessed. The associations were tested using generalized linear models adjusted for confounders. Results:The PPARG2 Pro12Ala polymorphism influenced body composition changes. Ala carriers in the intervention groups with extra virgin olive oil supplementation had greater reductions in the percentage of body fat (%BF) (OO: p?=?0.049, DietBra+OO: p?=?0.004) and greater increases in both fat-free mass (FFM) (OO: p?=?0.020, DieTBra: p?=?0.007) and lean mass (LM) (OO: p?=?0.020, DieTBra+OO: p?=?0.007) than did ProPro homozygotes. No association was found for the IL6 -174G?>?C polymorphism. Conclusions:Extra virgin olive oil intake may modulate favourable body composition changes, promoting a decrease in the %BF and increases in the LM and FFM of severely obese individuals, even without weight loss, in the presence of the Ala allele of the Pro12Ala polymorphism. Trial registration:Registered under ClinicalTrials.gov Identifier No. NCT02463435.

SUBMITTER: Rodrigues APS 

PROVIDER: S-EPMC6050653 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature